Will Cogent Biosciences’ (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So

Cogent Biosciences Inc. (NASDAQ:COGT) is among the hottest SMID-cap stocks so far in 2025. On November 13, H.C. Wainwright made a notable upward revision to its outlook on the company, more than doubling its price target from $21 to $50 while reaffirming a Buy rating, according to TheFly. The investment firm’s increased confidence was driven by positive data from the company’s Phase 3 PEAK trial, which studied the combination of its therapy, bezuclastinib, with sunitinib. Following the announcement, the a ...